In an era where practice in hepatology has been revolutionised by an avalanche of therapeutic breakthroughs, hepatocellular carcinoma (HCC) still stands as the most difficult to cure end-stage liver disease and the dominant cause of death of patients with compensated cirrhosis of any aetiology. In 2012, the death toll of HCC was impressive, resulting from 521,000 men and 224,500 women estimated to have died from liver cancer, meaning that this cancer was the second leading cause of cancer death in men and the sixth in women, worldwide.
To read the full article visit: The Journal of Hepatology
New study evaluates efficacy of PET imaging to manage chronic liver diseases
EASL governing board announces new Vice-Secretary
A web-based program is as effective as group counseling for patients with non-alcoholic fatty liver disease